Proboka G - Search Results

1

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report.

Proboka G, Rasa A, Olmane E, Isajevs S, Tilgase A, Alberts P. Proboka G, et al. Medicine (Baltimore). 2019 Nov;98(45):e17883. doi: 10.1097/MD.0000000000017883. Medicine (Baltimore). 2019. PMID: 31702662 Free PMC article.

2

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.

Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D. Alberts P, et al. Among authors: proboka g. APMIS. 2016 Oct;124(10):896-904. doi: 10.1111/apm.12576. Epub 2016 Jul 26. APMIS. 2016. PMID: 27457663

3

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report.

Proboka G, Tilgase A, Isajevs S, Rasa A, Alberts P. Proboka G, et al. Front Oncol. 2018 Feb 26;8:43. doi: 10.3389/fonc.2018.00043. eCollection 2018. Front Oncol. 2018. PMID: 29535971 Free PMC article.

4

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir.

Proboka G, Tilgase A, Isajevs S, Zablocka T, Olmane E, Rasa A, Alberts P. Proboka G, et al. Case Rep Oncol. 2020 Apr 17;13(1):424-430. doi: 10.1159/000506978. eCollection 2020 Jan-Apr. Case Rep Oncol. 2020. PMID: 32399011 Free PMC article.

5

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.

Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A. Doniņa S, et al. Among authors: proboka g. Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180. Melanoma Res. 2015. PMID: 26193376 Free PMC article.

6

Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.

Veinalde R, Ozola A, Azarjana K, Molven A, Akslen LA, Doniņa S, Proboka G, Cēma I, Baginskis A, Pjanova D. Veinalde R, et al. Among authors: proboka g. Melanoma Res. 2013 Jun;23(3):221-6. doi: 10.1097/CMR.0b013e3283608695. Melanoma Res. 2013. PMID: 23546221

7

Melanoma risk associated with MC1R gene variants in Latvia and the functional analysis of rare variants.

Ozola A, Azarjana K, Doniņa S, Proboka G, Mandrika I, Petrovska R, Cēma I, Heisele O, Eņģele L, Streinerte B, Pjanova D. Ozola A, et al. Among authors: proboka g. Cancer Genet. 2013 Mar;206(3):81-91. doi: 10.1016/j.cancergen.2013.01.002. Epub 2013 Mar 20. Cancer Genet. 2013. PMID: 23522749

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters